Cagrilintide: difference between revisions
Diff·revision 2 → 3·05:11, 27 Aug 2024
Difference between revision 2 and revision 3 of Cagrilintide. 5 lines changed; the page grew by 594 bytes.
| Revision 2 — 21:16, 17 Aug 2024 COA_Colwyn (talk) give the INN alongside the trade name at first mention 1,293 bytes ±0 | Revision 3 — 05:11, 27 Aug 2024 GradientGus (talk) the storage condition applies to the unopened pen; say so 1,887 bytes +594 | ||
|---|---|---|---|
| 11 | Its actions follow those of amylin: slowed [[Gastric emptying|gastric emptying]], suppression of postprandial glucagon, and reduced food intake through hindbrain circuits distinct from the [[GLP-1 receptor|GLP-1]] pathway.{{r|hay2015}} | 11 | Its actions follow those of amylin: slowed [[Gastric emptying|gastric emptying]], suppression of postprandial glucagon, and reduced food intake through hindbrain circuits distinct from the [[GLP-1 receptor|GLP-1]] pathway.{{r|hay2015}} |
| 12 | 12 | ||
| + | 13 | == Design == | |
| + | 14 | The engineering problem is the same one pramlintide solved differently. Human amylin forms fibrils at concentrations well below those a formulation requires, so a developable analogue must break the β-sheet propensity of the central region while retaining receptor activity.{{r|hay2015}} | |
| + | 15 | ||
| + | 16 | Cagrilintide adds acylation to that, giving the long half-life the earlier mealtime analogue lacked. It engages the calcitonin receptor as well as the amylin receptor complexes, and whether that broader engagement contributes to or detracts from the effect is not established.{{r|lau2021}} | |
| + | 17 | ||
| 13 | == References == | 18 | == References == |
| 14 | {{reflist}} | 19 | {{reflist}} |